Gilead Sciences, headquartered in Foster City, California, employs 18,000 people and focuses on developing medicines for HIV, hepatitis, COVID-19, and cancer. Its portfolio includes numerous marketed products and several promising candidates.
Kelly A Kramer sold 2,805 shares of GILD on 28 November at $127.10 per share, worth a total of $357K. They now own 1,339 GILD shares, or a 68% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.